CA2699550C - Method of inhibiting clostridium difficile by administration of oritavancin - Google Patents

Method of inhibiting clostridium difficile by administration of oritavancin Download PDF

Info

Publication number
CA2699550C
CA2699550C CA2699550A CA2699550A CA2699550C CA 2699550 C CA2699550 C CA 2699550C CA 2699550 A CA2699550 A CA 2699550A CA 2699550 A CA2699550 A CA 2699550A CA 2699550 C CA2699550 C CA 2699550C
Authority
CA
Canada
Prior art keywords
glycopeptide antibiotic
effective amount
therapeutically effective
body weight
difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2699550A
Other languages
English (en)
French (fr)
Other versions
CA2699550A1 (en
Inventor
Mark Harvey Wilcox
Simon Baines
Dario Lehoux
Thomas R. Parr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of CA2699550A1 publication Critical patent/CA2699550A1/en
Application granted granted Critical
Publication of CA2699550C publication Critical patent/CA2699550C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2699550A 2007-09-12 2008-09-11 Method of inhibiting clostridium difficile by administration of oritavancin Active CA2699550C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97176607P 2007-09-12 2007-09-12
US60/971,766 2007-09-12
PCT/US2008/075949 WO2009036121A1 (en) 2007-09-12 2008-09-11 Method of inhibiting clostridium difficile by administration of oritavancin

Publications (2)

Publication Number Publication Date
CA2699550A1 CA2699550A1 (en) 2009-03-19
CA2699550C true CA2699550C (en) 2020-08-18

Family

ID=40452464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699550A Active CA2699550C (en) 2007-09-12 2008-09-11 Method of inhibiting clostridium difficile by administration of oritavancin

Country Status (9)

Country Link
US (3) US8518873B2 (enExample)
EP (1) EP2195004B1 (enExample)
JP (1) JP5591112B2 (enExample)
CN (1) CN102316885A (enExample)
AU (1) AU2008298987B2 (enExample)
CA (1) CA2699550C (enExample)
EA (1) EA017564B1 (enExample)
ES (1) ES2535928T3 (enExample)
WO (1) WO2009036121A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518873B2 (en) * 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
ES2884673T3 (es) * 2008-04-08 2021-12-10 Melinta Therapeutics Inc Oritavancina para inhibir y tratar biopelículas
PT2424559T (pt) * 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
JP5986416B2 (ja) * 2012-04-11 2016-09-06 花王株式会社 皮膚外用剤
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
MX369877B (es) * 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
JP2016519664A (ja) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6553074B2 (ja) * 2014-10-14 2019-07-31 アーゼッド・エレクトロニック・マテリアルズ（ルクセンブルグ）ソシエテ・ア・レスポンサビリテ・リミテ レジストパターン処理用組成物およびそれを用いたパターン形成方法
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CA3014294A1 (en) 2016-02-18 2017-08-24 Melinta Therapeutics, Inc. Oritavancin formulations
CN107325159A (zh) * 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
MX388732B (es) 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
CA3109900A1 (en) * 2018-08-17 2020-02-20 Universidad Andres Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile
KR102444119B1 (ko) * 2020-04-22 2022-09-16 주식회사 인트론바이오테크놀로지 클로스트리디오이데스 디피실리 균에 대하여 용균 활성을 갖는 항균단백질 cdl200

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961184B2 (ja) * 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
AU2003240545A1 (en) * 2002-06-06 2003-12-22 Therapeutics Corporation Genome Use of ramoplanin to treat diseases associated with the use of antibiotics
ATE448775T1 (de) * 2002-08-29 2009-12-15 Activbiotics Pharma Llc Rifalazil zur behandlung von infektionen mit clostridium difficile
CN1918172B (zh) * 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
WO2007092582A2 (en) * 2006-02-08 2007-08-16 Biosynexus Incorporated Neutralization of bacterial spores
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
US8518873B2 (en) * 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin

Also Published As

Publication number Publication date
EA201000383A1 (ru) 2010-10-29
EP2195004A1 (en) 2010-06-16
US8518873B2 (en) 2013-08-27
BRPI0816662A2 (pt) 2017-06-13
US20140100157A1 (en) 2014-04-10
US8629100B2 (en) 2014-01-14
US20130310308A1 (en) 2013-11-21
EP2195004B1 (en) 2015-04-01
EP2195004A4 (en) 2011-12-28
AU2008298987B2 (en) 2013-12-05
CA2699550A1 (en) 2009-03-19
JP2010539179A (ja) 2010-12-16
US20100311646A1 (en) 2010-12-09
WO2009036121A1 (en) 2009-03-19
JP5591112B2 (ja) 2014-09-17
ES2535928T3 (es) 2015-05-19
EA017564B1 (ru) 2013-01-30
CN102316885A (zh) 2012-01-11
AU2008298987A1 (en) 2009-03-19
US9220749B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
AU2008298987B2 (en) Method of inhibiting clostridium difficile by administration of oritavancin
ES2884673T3 (es) Oritavancina para inhibir y tratar biopelículas
CA2736860C (en) Methods of treatment using single doses of oritavancin
CA2664444C (en) Use of oritavancin for prevention and treatment of anthrax
EP3038615A2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
BRPI0816662B1 (pt) Método in vitro para inibir crescimento de esporo de c. difficile
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240808

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251205

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260422

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713